| Literature DB >> 28476722 |
Adnan A Hyder1,2, Adaeze C Wosu3, Dustin G Gibson1, Alain B Labrique1, Joseph Ali1,2, George W Pariyo1.
Abstract
Noncommunicable diseases (NCDs) account for two-thirds of all deaths globally, with 75% of these occurring in low- and middle-income countries (LMICs). Many LMICs seek cost-effective methods to obtain timely and quality NCD risk factor data that could inform resource allocation, policy development, and assist evaluation of NCD trends over time. Over the last decade, there has been a proliferation of mobile phone ownership and access in LMICs, which, if properly harnessed, has great potential to support risk factor data collection. As a supplement to traditional face-to-face surveys, the ubiquity of phone ownership has made large proportions of most populations reachable through cellular networks. However, critical gaps remain in understanding the ways by which mobile phone surveys (MPS) could aid in collection of NCD data in LMICs. Specifically, limited information exists on the optimization of these surveys with regard to incentives and structure, comparative effectiveness of different MPS modalities, and key ethical, legal, and societal issues (ELSI) in the development, conduct, and analysis of these surveys in LMIC settings. We propose a research agenda that could address important knowledge gaps in optimizing MPS for the collection of NCD risk factor data in LMICs and provide an example of a multicountry project where elements of that agenda aim to be integrated over the next two years. ©Adnan A Hyder, Adaeze C Wosu, Dustin G Gibson, Alain B Labrique, Joseph Ali, George W Pariyo. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 05.05.2017.Entities:
Keywords: mHealth; mobile phone; noncommunicable disease; research agenda; survey
Mesh:
Year: 2017 PMID: 28476722 PMCID: PMC5438453 DOI: 10.2196/jmir.7246
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Summary of the World Health Organization (WHO) 9 voluntary targets and 25 indicators for global noncommunicable disease (NCD) monitoring [1].
| Element | Targets | Relevant indicators | |
| Premature mortality from NCD | 25% reduction in premature mortality from NCD | Unconditional probability of death between ages 30 and 70 years from the 4 main NCDs | |
| Cancer incidence, by type of cancer, per 100,000 population | |||
| Harmful use of alcohol | 10% reduction in harmful use of alcohol | Total (recorded, unrecorded) alcohol per capita (in ≥15 years old) consumption within a calendar year in liters pure alcohol | |
| Age-standardized prevalence of heavy episodic drinking among adolescents and adults | |||
| Alcohol-related morbidity and mortality among adolescents and adults | |||
| Physical inactivity | 10% reduction in prevalence of physical inactivity | Prevalence of insufficiently active adolescents, defined as <60 min of moderate or vigorous intensity activity daily | |
| Age-standardized prevalence of insufficiently active persons, aged ≥18 years (defined as <150 min moderate activity per week, or equivalent) | |||
| Salt or sodium intake | 30% reduction in mean population intake of salt or sodium | Age-standardized mean population intake of salt (sodium chloride) per day in grams in persons ≥18 years old | |
| Tobacco use | 30% reduction in prevalence of tobacco use | Prevalence of current tobacco use among adolescents | |
| Age-standardized prevalence of current tobacco use among persons ≥18 years old | |||
| Raised blood pressure | 25% reduction in prevalence of raised blood pressure or contain the prevalence of raised blood pressure | Age-standardized prevalence of raised blood pressure among persons ≥18 years old (defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg); and mean systolic blood pressure | |
| Diabetes and obesity | 0% increase in diabetes or obesity | Age-standardized prevalence raised blood glucose or diabetes among ≥18 years old (fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) or on medication for raised blood glucose) | |
| Prevalence overweight or obesity in adolescents (WHO growth reference for school-aged children and adolescents) | |||
| Age-standardized prevalence of overweight or obesity ≥18 years (body mass index ≥25 kg/m²; overweight ≥30 kg/m² obesity) | |||
| Age-standardized mean proportion of total energy intake from saturated fatty acids in persons ≥18 years old | |||
| Age-standardized prevalence (≥18 years old) consuming less than five total servings (400 g) of fruit or vegetables per day | |||
| Age-standardized prevalence raised total cholesterol aged ≥18 years (total cholesterol ≥5.0 mmol/L or 190 mg/dL) | |||
| Drug therapies to prevent heart attacks and strokes | ≥50% coverage in eligible individuals in drug therapy and counseling | Proportion of eligible persons (defined as ≥40 years old with a 10-year cardiovascular risk of ≥30%, including those with existing CVD) receiving drug therapy and counseling (including glycemic control) to prevent heart attacks and strokes | |
| Essential NCD medicines and basic technologies to treat major NCDs | 80% coverage for technologies and essential NCD medicines to treat NCD in public and private facilities | Availability and affordability of quality, safe and efficacious essential NCD medicines, including generics, and basic technologies in both public and private facilities | |
| Access to palliative care assessed by morphine-equivalent consumption of strong opioid per death from cancer | |||
| Adoption of national policies that limit saturated fatty acids and virtually eliminate partially hydrogenated vegetable oils in the food supply | |||
| Availability of cost-effective and affordable vaccines against human papillomavirus | |||
| Policies to reduce the impact on children of marketing of foods and nonalcoholic beverages high in saturated fats, trans fatty acids, free sugars, or salt | |||
| Vaccination coverage hepatitis B by number of third doses of Hepatitis-B vaccine (HepB3) administered to infants | |||
| Proportion of women 30-49 years screened for cervical cancer at least once | |||
aNCD: noncommunicable disease.
bmmol: millimole.
cmg: milligram.
ddL: deciliter.
eWHO: World Health Organization.
fCVD: cardiovascular disease.
Proposed research agenda for mobile phone survey (MPS) and noncommunicable disease (NCD) risk factor data collection
| Goals | Objectives | BD4HI |
| Goal 1: | Exploring the usability or technical requirements of MPS modalities, community perceptions, and willingness to take MPS. | The project will (1) identify lessons learned and challenges from individuals with experience of MPS (via key informant interviews); (2) understand community acceptance and willingness to respond to IVR (via focus group discussions); and (3) examine and refine the usability of an NCD risk factor survey delivered through an IVR platform (via semi-structured interviews). |
| Exploring the impact of incentive amounts, incentive timing, and incentive structure on key MPS metrics. | Test impact of different incentive factors on key survey metrics; participants to receive different incentive (1) amounts (including none), (2) timing (prepaid to poststudy), and (3) structures (fixed, lottery). | |
| Exploring the impact of the content, type, and modality of introductory messages on key MPS metrics. | Exploring the impact of different content (informational, motivational) and voice (male, female) of IVR introduction. | |
| Exploring the impact of different sampling frames on key MPS metrics. | Assess the benefit of using random digit dialing (RDD) compared with a list of preexisting phone numbers | |
| Exploring the impact of specific questions and their order on key MPS metrics. | Examine impact of different orders of NCD modules (eg, diet, tobacco use, alcohol) on key survey metrics. | |
| Goal 2: | Assess impact of MPS modality on key metrics, performance characteristics, and costs of MPS. | Participants will respond to either CATI or IVR using the same questionnaire; and response characteristics will be studied. |
| Compare national or subnational indicators between MPS modalities. | Responses of participants to IVR and CATI surveys will be compared. | |
| MPS intermodal reliability and response consistency. | Participants will be randomized to one of two arms: IVR then CATI, or CATI then IVR. The questionnaires used in both study arms will be the same. Crossover design will allow for an assessment of response consistency | |
| Goal 3: | Determine key ethical issues in the conduct of MPS. | Conduct of a systematic review of the literature to collect the most common ELSI and collate them according to broad themes. |
| Describe common and preferred practices for obtaining individual consent or permission for MPS. | Conduct a survey of researchers, programmers, users, and stakeholders of MPS on and from LMICs to help define the prevalence of key ELSI; and how they have been addressed. | |
| Document commonly encountered regulatory complexities when conducting MPS and how have they been addressed. | ||
| Identify key societal goals and values that are supportive of MPS and how these are balanced against other important interests. |
aBD4HI: Bloomberg Data for Health Initiative.
bMPS: mobile phone surveys.
cNCDs: noncommunicable diseases.
dIVR: interactive voice response.
eCATI: computer-assisted telephone interview.
fELSI: ethical, legal, and societal issues.
gLMICs: low- and middle-income countries.
Bloomberg Data for Health Project—key goals, components, and partners.
| Key features | Description |
| Overall goal | To improve the health of populations through strengthening collection and use of public health data |
| Components | Civil Registration and Vital Statistics (CRVS) Improvement |
| Partners | Centers for Disease Control and Prevention, USA |
| Donors | Bloomberg Philanthropies |